-transparent.png){kind=logo}
The histochemical characteristics of a Mr 29,000 phosphoprotein related to estradiol receptor are described in a large series of human breast tumors. The antigen was detected with a monoclonal antibody (D5) raised against partially purified human myometrial estradiol receptor. An indirect immunoperoxidase method was used with methacarn-fixed, wax-embedded sections. Quantitation of staining and its reproducibility are described. Results with trucut biopsies agree with those obtained with larger tumor sections. Normal breast is infrequently positive. Histochemical staining is higher in invasive carcinoma than in normal breast with ductal carcinoma in situ adjacent to infiltrating tumors exhibiting intermediate values. Furthermore, most in situ carcinomas have a heterogeneous staining pattern. About 20% of invasive tumors also exhibit heterogeneity. No simple correlation is seen between staining and histological grade. There are more low-staining tumors in young (less than 50 yr old) patients than in older women. Staining correlates with levels of cytosol estradiol receptor but not cytosol progesterone receptor. However, cytosol estradiol receptor-negative, cytosol progesterone receptor-positive tumors tend to have positive Mr 29,000 phosphoprotein levels. Positive staining is associated with a higher response rate to hormone therapy (50%). None of the negative tumors responded to hormone treatment. With these patients, comparison of histochemical assay for Mr 29,000 phosphoprotein and [3H]estradiol binding assays indicated that the former was at least as good as the latter assay in predicting hormone response. About 20% of cytosol estradiol receptor-positive tumors have low Mr 29,000 phosphoprotein, and such tumors have poor response to hormone treatment.
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
January 1988,
Gynecologic and obstetric investigation,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
July 1990,
Cancer research,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
March 1984,
Cancer research,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
July 1997,
The Journal of clinical endocrinology and metabolism,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
June 1987,
British journal of cancer,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
June 1952,
Acta pathologica et microbiologica Scandinavica. Supplementum,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
January 1990,
Biochemical and biophysical research communications,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
December 1975,
The Western journal of medicine,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
February 1992,
Cancer,
A Cano, and
A I Coffer, and
R Adatia, and
R R Millis, and
R D Rubens, and
R J King
July 1987,
Pathology,
